JP2024543457A - 保存製剤 - Google Patents

保存製剤 Download PDF

Info

Publication number
JP2024543457A
JP2024543457A JP2024527771A JP2024527771A JP2024543457A JP 2024543457 A JP2024543457 A JP 2024543457A JP 2024527771 A JP2024527771 A JP 2024527771A JP 2024527771 A JP2024527771 A JP 2024527771A JP 2024543457 A JP2024543457 A JP 2024543457A
Authority
JP
Japan
Prior art keywords
concentration
composition
composition according
bif
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543457A5 (https=
Inventor
ポール アレン，デイビッド
マイケル ビールス，ジョン
ジョン コーバリ，ビンセント
ダニエル ドノヴァン，パトリック
カンイー チャン，カン
ワン，ウェイ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024543457A publication Critical patent/JP2024543457A/ja
Publication of JP2024543457A5 publication Critical patent/JP2024543457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024527771A 2021-11-15 2022-11-14 保存製剤 Pending JP2024543457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279390P 2021-11-15 2021-11-15
US63/279,390 2021-11-15
PCT/US2022/079791 WO2023086980A1 (en) 2021-11-15 2022-11-14 Preserved formulations

Publications (2)

Publication Number Publication Date
JP2024543457A true JP2024543457A (ja) 2024-11-21
JP2024543457A5 JP2024543457A5 (https=) 2025-04-04

Family

ID=84537390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527771A Pending JP2024543457A (ja) 2021-11-15 2022-11-14 保存製剤

Country Status (19)

Country Link
US (1) US20250000950A1 (https=)
EP (1) EP4433024A1 (https=)
JP (1) JP2024543457A (https=)
KR (1) KR20240082407A (https=)
CN (1) CN118302152A (https=)
AR (1) AR127619A1 (https=)
AU (1) AU2022386352B2 (https=)
CA (1) CA3238180A1 (https=)
CL (1) CL2024001415A1 (https=)
CO (1) CO2024006121A2 (https=)
CR (1) CR20240202A (https=)
DO (1) DOP2024000084A (https=)
EC (1) ECSP24036789A (https=)
IL (1) IL312623A (https=)
JO (1) JOP20240108A1 (https=)
MX (1) MX2024005879A (https=)
PE (1) PE20241354A1 (https=)
TW (1) TWI871539B (https=)
WO (1) WO2023086980A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542236A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
JP2015524428A (ja) * 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリン結合体の液状製剤
JP2018515088A (ja) * 2015-05-07 2018-06-14 イーライ リリー アンド カンパニー 融合タンパク質
WO2021055505A2 (en) * 2019-09-17 2021-03-25 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin and glucagon formulations and methods of administration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
WO2021119607A1 (en) * 2019-12-13 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542236A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
JP2015524428A (ja) * 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリン結合体の液状製剤
JP2018515088A (ja) * 2015-05-07 2018-06-14 イーライ リリー アンド カンパニー 融合タンパク質
WO2021055505A2 (en) * 2019-09-17 2021-03-25 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin and glucagon formulations and methods of administration

Also Published As

Publication number Publication date
TW202339790A (zh) 2023-10-16
JOP20240108A1 (ar) 2024-05-14
KR20240082407A (ko) 2024-06-10
ECSP24036789A (es) 2024-06-28
PE20241354A1 (es) 2024-07-03
MX2024005879A (es) 2024-05-29
CR20240202A (es) 2024-06-11
CL2024001415A1 (es) 2024-10-18
CN118302152A (zh) 2024-07-05
DOP2024000084A (es) 2024-06-16
EP4433024A1 (en) 2024-09-25
AU2022386352A1 (en) 2024-05-09
AR127619A1 (es) 2024-02-14
IL312623A (en) 2024-07-01
US20250000950A1 (en) 2025-01-02
WO2023086980A1 (en) 2023-05-19
CO2024006121A2 (es) 2024-06-27
AU2022386352B2 (en) 2025-12-18
TWI871539B (zh) 2025-02-01
CA3238180A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
KR101084412B1 (ko) 코팅된 제약 용기 내 안정화된 액상 단백질 제제
JP5851695B2 (ja) 安定な液体インターフェロン処方物
EA031134B1 (ru) Быстродействующие композиции инсулина
JP2014208656A (ja) 成長ホルモン製剤
US20180236079A1 (en) Stabilized glucagon solutions
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
IL280362B1 (en) Inhibition of kidney disease relapse by targeted cytokine depletion
AU2008291309B2 (en) Liquid formulation of G-CSF
AU2022386352B2 (en) Preserved formulations
HK40077155A (en) A lyophilised pharmaceutical formulation and its use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402